Refine
Has Fulltext
- yes (46)
Is part of the Bibliography
- yes (46)
Year of publication
- 2013 (46) (remove)
Document Type
- Journal article (29)
- Doctoral Thesis (17)
Keywords
- cytokines (3)
- heart failure (3)
- mortality (3)
- myocardial infarction (3)
- prognosis (3)
- Fabry disease (2)
- Hämodialyse (2)
- cardiac hypertrophy (2)
- cardiovascular disease (2)
- cardiovascular diseases (2)
- cardiovascular events (2)
- chronic kidney disease (2)
- cognitive decline (2)
- enzyme replacement therapy (2)
- hemodialysis (2)
- inflammation (2)
- postmenopausal women (2)
- risk factors (2)
- sudden cardiac death (2)
- A-delta fibers (1)
- Addisons disease (1)
- Aldosteron (1)
- Aldosteronsynthaseinhibitor (1)
- Apoptose (1)
- Apoptosis (1)
- Arteriosklerose (1)
- Atherosklerose (1)
- Bildgebung (1)
- Biokompatibilität (1)
- Bioluminescence (1)
- Biomarker (1)
- Blut (1)
- C-reaktives Protein (1)
- CCR2 (1)
- CX3CR1 (1)
- CXCR4 (1)
- CYP11B2 (1)
- Ca2+i handling (1)
- Calibration (1)
- Cardiac magnetic resonance imaging (1)
- Cell (1)
- Chemokinrezeptoren (1)
- Chronische Herzinsuffizienz (1)
- Chronische Niereninsuffizienz (1)
- Clinical prediction rule (1)
- Cortisol (1)
- DCM (1)
- DHEA (1)
- DHEA-Sulfotransferase (1)
- Dehydroepiandrosteron (1)
- Diabetes (1)
- Diagnostik / Bildgebendes Verfahren (1)
- Dialyse (1)
- Dilated Cardiomyopathy (1)
- Dosierungen von Herzinsuffizienzmedikamenten (1)
- E193 (1)
- Elektrokardiogramm (1)
- Endothelial dysfunction (1)
- Endotheliale Dysfunktion (1)
- Endothelzelle (1)
- Endothelzellen (1)
- Enzyminhibitor (1)
- Enzyminhibitoren (1)
- Extracorporeal membrane oxygenation (1)
- Eya4 (1)
- Fabry (1)
- Fabry nephropathy (1)
- Fabry patient (1)
- Fabry-Krankheit (1)
- False positive reactions (1)
- Fetuin-A (1)
- Fibroblast-Growth-Factor-23 (1)
- GFR (1)
- GLA protein UCMGP (1)
- GMPcGMP-dependent protein kinase I (1)
- Genexpression (1)
- Glutathion (1)
- Heart failure (1)
- Hepcidin (1)
- Herzinfarkt (1)
- Herzinsuffizienz (1)
- Herzkatheter (1)
- Hyperaldosteronismus (1)
- Hämodiafiltration (1)
- Infection control (1)
- Inflammation (1)
- Ionenstärke (1)
- Ionic strength (1)
- KHK (1)
- Kalzifikation (1)
- Kardiologie (1)
- Kidney transplantation (1)
- Komorbiditäten (1)
- Komplikationen (1)
- Kontrastmittel (1)
- Kosten (1)
- L-arginine (1)
- LV mass (1)
- Langzeitprognose (1)
- Lyso Gb3 (1)
- Lyso-Gb3 (1)
- MRP-1 (1)
- Matrix-Gla-Protein (1)
- Methicillin-resistant staphylococcus aureus (1)
- Mikroarray (1)
- Mitotane Nebennierenkarzinom (1)
- Monozyten (1)
- Multidrug Resistance Protein-1 (1)
- Myocardial infarction (1)
- Nebenniere (1)
- Nierentransplantation (1)
- Nrf2 (1)
- PAPSS2 (1)
- PCI (1)
- Pain-related evoked potentials (1)
- Paricalcitol (1)
- Pharmakotherapie (1)
- Phosphoadenosinphosphosulfat (1)
- Plötzlicher Herztod (1)
- Predictive value of tests (1)
- Primärer Hyperaldosteronismus (1)
- Proteinbindung (1)
- Reactive Oxygen Species (1)
- Reaktive Sauerstoffspezies (1)
- Remodeling (1)
- Simulation (1)
- Simulator (1)
- Small fiber neuropathy (1)
- Streptozotocin (1)
- Superparamagnetische Eisenoxid Kontrastmittel (1)
- T cells (1)
- TNF-alpha (1)
- Telemetrie (1)
- Toxin (1)
- Transplantatfunktion (1)
- Tumor-Nekrose-Faktor (1)
- United States (1)
- Urämie (1)
- Urämietoxine (1)
- VCAM (1)
- Ventricular septal rupture (1)
- Virtual-Reality (1)
- Virtuelle Realität (1)
- Vitamin D (1)
- Zellkultur (1)
- Zelllinie (1)
- adenomas (1)
- adrenal (1)
- adult patients (1)
- agalsidase-beta (1)
- aging (1)
- aldosterone (1)
- alkaline phosphatase (1)
- alpha -Galaktosidase (1)
- alpha- Galactosidase (1)
- alpha-galactosidase-A (1)
- amyloidosis (1)
- anxiety (1)
- aorta (1)
- aortic valve (1)
- aortic valve disease (1)
- apoptosis (1)
- atherosclerosis (1)
- bardoxolone methyl (1)
- biocompatibility (1)
- biopsy findings (1)
- blood (1)
- blood pressure (1)
- blood-glucose control (1)
- body weight (1)
- bone formation (1)
- bone mineral density (1)
- brain natriuretic peptide (1)
- calcium (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinomas (1)
- cardiac energy metabolism (1)
- cardiac transplantation (1)
- cardiac ventricles (1)
- cardiovascular care (1)
- cardiovascular death (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular morbidity (1)
- cell lines (1)
- cell staining (1)
- central nervous system (1)
- chromosomes (1)
- chronic kidney-disease (1)
- circadian therapy (1)
- clinical trial (1)
- cognitive impairment (1)
- complication (1)
- computed tomography (1)
- cornea verticillata (1)
- coronary calcification (1)
- coronary-artery calcification (1)
- cortisol (1)
- costs (1)
- creatine synthesis (1)
- cyclic (1)
- deformation (1)
- depression (1)
- diabetes complications (1)
- diabetes mellitus (1)
- diabetes mellitus type 2 (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- dialysis (1)
- echocardiography (1)
- ejection fraction (1)
- end stage renal disease (1)
- end-stage renal disease (1)
- epidemiology (1)
- extracellular matrix (1)
- extracellular matrix remodeling (1)
- fall (1)
- fetuin A (1)
- fibrosis (1)
- focal semental glomerulosclerosis (1)
- fracture (1)
- genetic loci (1)
- genetics (1)
- genome-wide association (1)
- glomerular filtration rate (1)
- glomerular-filtration-rate (1)
- glucocorticoid replacement regimens (1)
- health care research (1)
- health questionnaire (1)
- heart (1)
- heart rate (1)
- heodialysis patients (1)
- homeostasis (1)
- hospitalization (1)
- hypertrophic cardiomyopathy (1)
- hypopituitary patients (1)
- immune cells (1)
- immuno-modulation (1)
- induced insulin-release (1)
- iron oxide contrast agent (1)
- kidney (1)
- kidney disease (1)
- kidney function (1)
- kidney-disease CKD (1)
- kidneys (1)
- laxative (1)
- left ventricular mass (1)
- left-ventricular hypertrophy (1)
- leitliniengerechte Therapie (1)
- lipoxygenase (1)
- magnetic resonance imaging (1)
- malignant tumors (1)
- medicine (1)
- metastasis (1)
- mineral metabolism (1)
- modified-release hydrocortisone (1)
- mouse (1)
- myocardium (1)
- natriuretic peptide (1)
- natural-history data (1)
- neurons (1)
- neutrophils (1)
- nictric-oxide (1)
- non-triggered (1)
- notch signaling (1)
- observational study (1)
- outcomes (1)
- phase-contrast CMR (1)
- podocyte (1)
- population (1)
- premature mortality (1)
- prevalence (1)
- protein binding (1)
- pulse-wave velocity (1)
- quality of life (1)
- radial (1)
- randomized controlled trial (1)
- rat kidney (1)
- reaktive Sauerstoffspezies (1)
- regression analysis (1)
- regulatory T cells (1)
- renal fibrosis (1)
- renal function (1)
- renal osteodystrophy (1)
- replacement therapy (1)
- retrospective (1)
- risk (1)
- scale (1)
- sclerostin (1)
- self-gating (1)
- septal hypertrophy (1)
- serum creatinine (1)
- short term (1)
- stage renal-disease (1)
- standardization (1)
- stem cell transplantation (1)
- stroke (1)
- subjective health-status (1)
- superparamagnetische Eisenoxid Kontrastmittel (1)
- surgical and invasive medical procedures (1)
- surgical repair (1)
- task force (1)
- telemetry (1)
- therapeutic management (1)
- treatment (1)
- trial design (1)
- type 2 diabetes (1)
- uremic toxin (1)
- urinary protein excretion (1)
- use (1)
- validation (1)
- validity (1)
- vascular calcification (1)
- vascular cell adhesion molecules (1)
- vascular surgery (1)
- vaskuläre Adhäsionsmoleküle (1)
- α-galactosidase A (1)
Institute
- Medizinische Klinik und Poliklinik I (46) (remove)
Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients.
Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers.
Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance.
Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies.
DHEA is a precursor for the male and female sex hormones testosterone and estradiol, which are mainly secreted from the testes and the ovary, respectively. In addition, epidemiological studies showed that low serum levels of DHEA and DHEAS correlate with the incidence of autoimmune disease, cancer and cardiovascular disease. In vitro, DHEA and DHEAS influenced glucose metabolism in a favourable manner. However, positive effects of DHEA substitution were only significant adrenal insufficiency in women.
Steroid sulphotransferase 2A1 (SULT2A1) is the responsible enzyme for sulphonation of DHEA to DHEAS which is thought to be the inactive form of DHEA. In this role, SULT2A1 acts as a central regulator of steroid synthesis because sulphonation of DHEA withdraws the substrate for further downstream conversion. Another essential cofactor for sulphonation is PAPS, which is produced by the enzyme PAPS synthase (PAPSS) from ATP and anorganic sulphate. PAPSS exists in the different isoforms PAPSS1 and PAPSS2 and splice variants PAPSS2a and PAPSS2b. Changes in PAPSS activity are thought to influence sulphonation of DHEA significantly. However, neither regulation of PAPSS nor its influence on SULT2A1 have been investigated in human cell lines or humans.
The main goal of this thesis was to analyze the enzyme expression of the DHEA/DHEA shuttle, i.e. mRNA and protein of SULT2A1, PAPSS1 and PAPSS2, in various human cell lines. Furthermore, I investigated which cell line could serve as a suitable model for further research regarding regulation of SULT2A1, PAPSS1 and PAPSS2.
Here, I could show that the enzymes of the DHEA/DHEAS shuttle were expressed in the human adrenal cell line NCI-h295R as both mRNA and protein. In enzyme assays, I was able to prove conversion of DHEA to DHEAS as well as to different other steroids. However, applying Trilostane, a potent inhibitor of CYP3B, effectively directed conversion of DHEA to DHEAS. Using these findings, future experiments can investigate for example the influence of certain cytokines or endocrine disruptors on expression and activity of PAPSS1/2 and on sulphonation of DHEA. In particular, the relatively equal expression of PAPSS1 and PAPSS2 will enable us to do knock down experiments with siRNA to elucidate how the activity of one enzyme changes when the other one fails.
Sulphonation of DHEA by SULT2A1 is thought to happen in the cytoplasm or more precisely in the Golgi apparatus. However, experiments in transfected cells have shown both a cytoplasmatic and a nuclear localisation when both enzymes were expressed at the same time. Immunocytochemistry revealed the same results in the adrenal cell line NCI-h295R, where both enzymes were expressed strongly in the nucleus. The physiological role is not clear and requires further research. Presumably, sulphate is activated in the nucleus. However, one could also speculate that a shift of PAPSS to the nucleus could generate a reservoir, which can be activated by re-localisation to the cytoplasm when more PAPS is needed.
Expression of SULT2A1 in some foetal tissues has been investigated earlier. Whilst in adult human cartilage PAPSS1 is predominant, in newly born hamsters PAPSS2 is more abundantly expressed. The expression of PAPSS isoforms in highly sulphonating tissue has not been investigated in humans, so far. This work demonstrated a differential expression of SULT2A1, PAPSS1 and PAPSS2 in adult and foetal liver, adrenal and foetal cartilage tissue. In adult and foetal adrenal expression was similar. However, foetal and adult liver differed in the expression of SULT2A1, which was expressed much more in adult tissue. Most importantly, in foetal cartilage there was only a low expression of SULT2A1 and PAPS seems to mostly provided by PAPSS1, which was considerably higher expressed in cartilage than in other tissues. In contrast, PAPSS2 was mainly expressed in adult and foetal adrenal.
Additionally, we reported a case of a female patient who had been investigated for hyperandrogenism. Two mutations in the PAPSS2 gene had led to massively reduced serum levels of DHEAS. One heterozygous mutation in the domain of the APS kinase of the PAPSS2 protein leads to substitution of one amino acid at position 48 (T48R). In vitro experiments showed a residual activity of 6% for this mutation. A second mutation in the ATP sulphurylase domain of PAPSS2 was found. The introduction of thymidine instead of cytidine leads to a stop codon, which is presumed to truncate the protein at position 329 (R329X). In vitro, no residual activity was seen for this mutation. The lack of PAPS reduces sulphonation of DHEA but also sulphonation of proteoglycanes, which leads to skeletal abnormalities. The abundance of DHEA enables massive downstream conversion to androgens leading to clinical features of hyperandrogenism. Regarding the bone abnormalities, it is interesting and surprising that activity of PAPSS1 compensated to a great extent in cartilage but was not able to keep up a more considerable sulphonation of DHEA. Possibly, the subcellular localisation might play a role in this scenario.
Adrenocortical tumors consist of benign adenomas and highly malignant carcinomas with a still incompletely understood pathogenesis. A total of 46 adrenocortical tumors (24 adenomas and 22 carcinomas) were investigated aiming to identify novel genes involved in adrenocortical tumorigenesis. High-resolution single nucleotide polymorphism arrays (Affymetrix) were used to detect copy number alterations (CNAs) and copy neutral losses of heterozygosity (cnLOH). Genomic clustering showed good separation between adenomas and carcinomas, with best partition including only chromosome 5, which was highly amplified in 17/22 malignant tumors. The malignant tumors had more relevant genomic aberrations than benign tumors, such as a higher median number of recurrent CNA (2631 vs 94), CNAs >100 Kb (62.5 vs 7) and CN losses (72.5 vs 5.5), and a higher percentage of samples with cnLOH (91% vs 29%). Within the carcinoma cohort, a precise genetic pattern (i.e. large gains at chr 5, 7, 12, and 19, and losses at chr 1, 2, 13, 17, and 22) was associated with a better prognosis (overall survival: 72.2 vs 35.4 months, P=0.063). Interestingly, >70% of gains frequent in beningn were also present in malignant tumors. Notch signaling was the most frequently involved pathway in both tumor entities. Finally, a CN gain at imprinted “IGF2” locus chr 11p15.5 appeared to be an early alteration in a multi-step tumor progression, followed by the loss of one or two alleles, associated with increased IGF2 expression, only in carcinomas. Our study serves as database for the identification of genes and pathways, such as Notch signaling, which could be involved in the pathogenesis of adrenocortical tumors. Using these data, we postulate an adenoma-carcinoma sequence for these tumors.
Background: The clinical signs of adrenal cortical insufficiency (incidence, ca. 25 per million per year; prevalence, ca. 400 per million) are nonspecific, and misdiagnoses are therefore common. Glucocorticoid substitution therapy has been in use for 50 years but is not a wholly adequate treatment. Our understanding of this disease remains incomplete in many ways.
Methods: We selectively searched the Medline database for publications on adrenal cortical insufficiency, with particular attention to studies from the year 2000 onward (search terms: "adrenal insufficiency" or "Addison's disease" or "hypopituitarism"). Results: Hydrocortisone substitution therapy is often given in doses of 10-25 mg/day, timed according to the circadian rhythm. Gastrointestinal and other, febrile infections account for 30-50% of life-threatening adrenocortical crises. Such crises affect 8 of 100 persons with adrenal cortical insufficiency per year and must be treated by the immediate administration of glucocorticoids and fluids. When persons with adrenal cortical insufficiency are acutely ill or are otherwise under unusual stress, they may need additional amounts of hydrocortisone, often in the range of 5-10 mg but occasionally as high as 200 mg. The sustained administration of excessive amounts of steroid can shorten patients' lives by several years. Inappropriate substitution therapy can cause other major medical conditions, such as metabolic syndrome and osteoporosis.
Conclusion: Important measures for the prevention of adrenocortical crises include improved care by treating physicians, education of patients and their families, the provision of emergency identifying documents, and the prescription of glucocorticoid emergency kits.
The effect of mild chronic renal failure (CRF) induced by 4/6-nephrectomy (4/6NX) on central neuronal activations was investigated by c-Fos immunohistochemistry staining and compared to sham-operated rats. In the 4/6 NX rats also the effect of the angiotensin receptor blocker, losartan, and the central sympatholyticum moxonidine was studied for two months. In serial brain sections Fos-immunoreactive neurons were localized and classified semiquantitatively. In 37 brain areas/nuclei several neurons with different functional properties were strongly affected in 4/6NX. It elicited a moderate to high Fos-activity in areas responsible for the monoaminergic innervation of the cerebral cortex, the limbic system, the thalamus and hypothalamus (e.g. noradrenergic neurons of the locus coeruleus, serotonergic neurons in dorsal raphe, histaminergic neurons in the tuberomamillary nucleus). Other monoaminergic cell groups (A5 noradrenaline, C1 adrenaline, medullary raphe serotonin neurons) and neurons in the hypothalamic paraventricular nucleus (innervating the sympathetic preganglionic neurons and affecting the peripheral sympathetic outflow) did not show Fos-activity. Stress- and pain-sensitive cortical/subcortical areas, neurons in the limbic system, the hypothalamus and the circumventricular organs were also affected by 4/6NX. Administration of losartan and more strongly moxonidine modulated most effects and particularly inhibited Fos-activity in locus coeruleus neurons. In conclusion, 4/6NX elicits high activity in central sympathetic, stress- and pain-related brain areas as well as in the limbic system, which can be ameliorated by losartan and particularly by moxonidine. These changes indicate a high sensitivity of CNS in initial stages of CKD which could be causative in clinical disturbances.
Background: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factorinducible 14 (Fn14) are upregulated after myocardial infarction (MI) in both humans and mice. They modulate inflammation and the extracellular matrix, and could therefore be important for healing and remodeling after MI. However, the function of TWEAK after MI remains poorly defined.
Methods and results: Following ligation of the left coronary artery, mice were injected twice per week with a recombinant human serum albumin conjugated variant of TWEAK (HSA-Flag-TWEAK), mimicking the activity of soluble TWEAK. Treatment with HSA-Flag-TWEAK resulted in significantly increased mortality in comparison to the placebo group due to myocardial rupture. Infarct size, extracellular matrix remodeling, and apoptosis rates were not different after MI. However, HSA-Flag-TWEAK treatment increased infiltration of proinflammatory cells into the myocardium. Accordingly, depletion of neutrophils prevented cardiac ruptures without modulating all-cause mortality.
Conclusion: Treatment of mice with HSA-Flag-TWEAK induces myocardial healing defects after experimental MI. This is mediated by an exaggerated neutrophil infiltration into the myocardium.
Background
Surgical procedures in small animal models of heart disease might evoke alterations in cardiac morphology and function. The aim of this study was to reveal and quantify such potential artificial early or long term effects in vivo, which might account for a significant bias in basic cardiovascular research, and, therefore, could potentially question the meaning of respective studies.
Methods
Female Wistar rats (n = 6 per group) were matched for weight and assorted for sham left coronary artery ligation or control. Cardiac morphology and function was then investigated in vivo by cine magnetic resonance imaging at 7 Tesla 1 and 8 weeks after the surgical procedure. The time course of metabolic and inflammatory blood parameters was determined in addition.
Results
Compared to healthy controls, rats after sham surgery showed a lower body weight both 1 week (267.5±10.6 vs. 317.0±11.3 g, n<0.05) and 8 weeks (317.0±21.1 vs. 358.7±22.4 g, n<0.05) after the intervention. Left and right ventricular morphology and function were not different in absolute measures in both groups 1 week after surgery. However, there was a confined difference in several cardiac parameters normalized to the body weight (bw), such as myocardial mass (2.19±0.30/0.83±0.13 vs. 1.85±0.22/0.70±0.07 mg left/right per g bw, p<0.05), or enddiastolic ventricular volume (1.31±0.36/1.21±0.31 vs. 1.14±0.20/1.07±0.17 µl left/right per g bw, p<0.05). Vice versa, after 8 weeks, cardiac masses, volumes, and output showed a trend for lower values in sham operated rats compared to controls in absolute measures (782.2±57.2/260.2±33.2 vs. 805.9±84.8/310.4±48.5 mg, p<0.05 for left/right ventricular mass), but not normalized to body weight. Matching these findings, blood testing revealed only minor inflammatory but prolonged metabolic changes after surgery not related to cardiac disease.
Conclusion
Cardio-thoracic surgical procedures in experimental myocardial infarction cause distinct alterations upon the global integrity of the organism, which in the long term also induce circumscribed repercussions on cardiac morphology and function. This impact has to be considered when analyzing data from respective animal studies and transferring these findings to conditions in patients.
Atherosclerosis is an active and progressive condition where the vascular cell adhesion molecules as VCAM-1 play a vital role controlling the recruitment of immune cells within the early and advanced plaques. Therefore targeting of VCAM-1 molecules with specific contrast agent bears the possibility to monitor the VCAM-1 expression, visualize the plaque progression starting at the early alterations, and help to establish early prevention of atherosclerosis before the origin of the thrombus formation, of which late recognition leads to myocardial infarction. Furthermore noninvasive magnetic resonance imaging (MRI) offers the benefit of combining the molecular and anatomic data and would thus enable specific detection of VCAM-1 targeted iron oxide contrast agent within inflammatory process of atherosclerosis. This thesis exactly presents the VCAM-1 concept as a suitable molecular approach and the potential of specific ultrasmall superparamagnetic iron oxide (USPIO) conjugated to the VCAM-1 binding peptide over unspecific non-targeted USPIO particles for evaluation of atherosclerosis. This work firstly demonstrated that selection of VCAM-1 molecules offers a good and potential strategy for imaging of atherosclerosis, as these vascular cell adhesion molecules are highly expressed in the early phase of inflammation and also continuously up-regulated within the advanced plaques. Secondly, this thesis showed the proof of principle and capability of the newly designed USPIO contrast agent conjugated to the specific cyclic peptide for VCAM-1 recognition. The experimental studies including ultra-high field MRI enabled further ex vivo and in vivo detection of applied USPIO-VCAM-1 particles within the aortic root region of early and advanced atherosclerotic plaques of 12 and 30 week old apolipoprotein E deficient (ApoE-/-) mice. Using a combination of histology and electron microscopy, this study for the first time pointed to distribution of targeted USPIO-VCAM-1 particles within plaque cells expressing VCAM-1 not only in luminal regions but also in deeper medial smooth muscle cell areas. Hence functionalized USPIO particles targeting VCAM-1 molecules allow specific and sensitive detection of early and advanced plaques at the molecular level, giving the new possibilities for early recognition of atherosclerotic plaques before the appearance of advanced and prone to rupture lesions. In contrast to the functionalized USPIO-VCAM-1, utilized non-targeted USPIO particles did not succeed in early plaque 6 identification limiting visualization of atherosclerosis to advanced forms in atherosclerotic ApoE-/- mice.
Die Simulationstechnologie in der Medizin hat in den letzten Jahren große Fortschritte gemacht. In der Zwischenzeit gibt es auch für Herzkatheteruntersuchungen und -interventionen „Virtual reality“ Simulatoren, die ein realistisches Training von Kathetereingriffen erlauben. Nicht geklärt ist bislang, ob Simulationstraining das Stressniveau des Untersuchers reduzieren kann.
Im Rahmen dieser Studie wurde zur Beantwortung der genannten Fragestellung der Effekt von Virtual-Reality-Training auf das Stressniveau von Anfängern in der interventionellen Kardiologie untersucht. Hierzu wurde eine randomisiert-stratifizierte Studie bei 33 Anfängern in der interventionellen Kardiologie durchgeführt. Die Probanden wurden in eine Kontroll- und Simulationsgruppe aufgeteilt. Die Simulationsgruppe erhielt ein achtstündiges intensives Training an verschiedenen Simulatoren, während die Kontrollgruppe kein Simulationstraining, sondern lediglich eine theoretische Wissensvermittlung erhielt. Alle Teilnehmer mussten unter realitätsnahen Umständen im Herzkatheterlabor der Universitätsklinik Würzburg innerhalb von 30 Minuten eine PCI an einem pulsatilen Herzkreislaufmodell durchführen. Die Probanden dokumentierten vor und nach der Prä- und Postevaluation ihr aktuelles „Befinden“ anhand eines psychologi-schen Fragebogens PANAS. Ebenso wurden die Probanden hinsichtlich ihrer manuellen Fähigkeiten nach einem strukturierten Evaluationsbogen von einem interventionell tätigen Kardiologen bewertet
Die Ergebnisse zeigten initial für die Parameter „aktiv, interessiert, freudig erregt, stark, angeregt, stolz, begeistert, wach, entschlossen und aufmerksam“ des Fragebogens PANAS keinen gruppenspezifischen Unterschied. Nach einem achtstündigen Simulationstraining gab die Simulationsgruppe eine signifikante Reduktion des Stressniveaus im Vergleich zur Kontrollgruppe an.
Die aktuelle Studie zeigte, dass das Training an den Virtual Reality Simulatoren die herkömmliche Ausbildung in effektiver Weise ergänzen kann.
Weitere Studien mit einer größeren und zugleich homogeneren Stichprobengröße sind nötig, um die genannten Hypothesen zu bestätigen.
Objectives
The aim of this study was to explore the left ventricular (LV) deformation changes and the potential impact of deformation on outcome in patients with proven light-chain (AL) amyloidosis and LV hypertrophy.
Background
Cardiac involvement in AL amyloidosis patients is associated with poor outcome. Detecting regional cardiac function by advanced non-invasive techniques might be favorable for predicting outcome.
Methods
LV longitudinal, circumferential and radial peak systolic strains (Ssys) were assessed by speckle tracking imaging (STI) in 44 biopsy-proven systemic AL amyloidosis patients with LV hypertrophy (CA) and in 30 normal controls. Patients were divided into compensated (n = 18) and decompensated (n = 26) group based on clinical assessment and followed-up for a median period of 345 days.
Results
Ejection fraction (EF) was preserved while longitudinal Ssys (LSsys) was significantly reduced in both compensated and decompensated groups. Survival was significantly reduced in decompensated group (35% vs. compensated 78%, P = 0.001). LSsys were similar in apical segments and significantly reduced in basal segments between two patient groups. LSsys at mid-segments were significantly reduced in all LV walls of decompensated group. Patients were further divided into 4 subgroups according to the presence or absence of reduced LSsys in no (normal), only basal (mild), basal and mid (intermediate) and all segments of the septum (severe). This staging revealed continuously worse prognosis in proportion to increasing number of segments with reduced LSsys (mortality: normal 14%, mild 27%, intermediate 67%, and severe 64%). Mid-septum LSsys<11% suggested a 4.8-fold mortality risk than mid-septum LSsys≥11%. Multivariate regression analysis showed NYHA class and mid-septum LSsys were independent predictors for survival.
Conclusions
Reduced deformation at mid-septum is associated with worse prognosis in systemic amyloidosis patients with LV hypertrophy.